---
title: "Livzon Pharmaceutical’s First-Quarter Profit Slips as Policy Shift and Seasonality Hit Revenue"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283852429.md"
description: "Livzon Pharmaceutical Group reported a decline in first-quarter 2026 results, with operating income of RMB2.871 billion and net profit of RMB577 million, down 9.73% and 9.39% year-on-year, respectively. The decrease is attributed to industry policy adjustments and seasonal demand fluctuations. However, net cash flow from operating activities increased by 12.8% to RMB817 million, and shareholders’ equity rose by 4.47%. The company maintains a stable balance sheet with total assets at RMB24.19 billion. Analysts currently rate the stock as a Sell with a price target of HK$22.99."
datetime: "2026-04-23T14:11:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283852429.md)
  - [en](https://longbridge.com/en/news/283852429.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283852429.md)
---

# Livzon Pharmaceutical’s First-Quarter Profit Slips as Policy Shift and Seasonality Hit Revenue

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest update is out from Livzon Pharmaceutical Group ( (HK:1513) ).

Livzon Pharmaceutical Group reported unaudited first-quarter 2026 results prepared under China Accounting Standards, showing operating income of RMB2.871 billion and net profit attributable to shareholders of RMB577 million. Operating income and net profit declined by 9.73% and 9.39% year on year, respectively, while basic earnings per share fell to RMB0.65 and return on net assets eased to 4.06%.

Management attributed the weaker top line to a transitional period of industry policy adjustments and seasonal fluctuations in influenza and respiratory infections, which weighed on demand in the quarter. Despite the softer revenue and profit, net cash flow from operating activities rose 12.8% to RMB817 million and shareholders’ equity increased 4.47%, indicating stable overall performance and resilient operating quality in the core business.

Total assets edged up 0.87% to RMB24.19 billion by the end of March, underscoring a broadly steady balance sheet position. The board and senior management affirmed the accuracy and completeness of the disclosed financial data, signaling a focus on transparency and compliance for investors amid a challenging policy and market environment.

The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.

**More about Livzon Pharmaceutical Group**

Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company listed in Hong Kong, operating as a joint stock company with limited liability. The group focuses on the development, production and sale of pharmaceutical products, serving the domestic healthcare market and leveraging its diversified portfolio to maintain resilient core operations.

**Average Trading Volume:** 914,703

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$31.41B

### Related Stocks

- [000513.CN](https://longbridge.com/en/quote/000513.CN.md)
- [01513.HK](https://longbridge.com/en/quote/01513.HK.md)

## Related News & Research

- [CICC Reaffirms Their Buy Rating on Livzon Pharmaceutical Group (LVZPF)](https://longbridge.com/en/news/282769048.md)
- [The Most Consistent Seasonal Trades Across Commodities—Backed by 15 Years of Data](https://longbridge.com/en/news/286648926.md)
- [Seasonal Maintenance Curbs US Nat-Gas Production and Boosts Prices](https://longbridge.com/en/news/286957048.md)
- [11:36 ETP.C. Richard & Son Helps Families Prepare for Memorial Day Weekend with Savings on Seasonal Home Essentials](https://longbridge.com/en/news/286440627.md)
- [U.S. commercial paper market grows in week-Fed](https://longbridge.com/en/news/286447081.md)